Patents by Inventor Judith Kempfle

Judith Kempfle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220259602
    Abstract: The present disclosure provides compositions and methods for treating subjects at risk for or with sensorineural hearing loss by modulating the rate of Atoh1 protein degradation to increase levels of Atoh1 protein.
    Type: Application
    Filed: March 4, 2022
    Publication date: August 18, 2022
    Inventors: Albert Edge, Yen-Fu Cheng, Judith Kempfle, Dunia Abdul-Aziz
  • Publication number: 20220249673
    Abstract: This invention relates to drug conjugates useful for localized treatment of diseases or disorders of the middle ear and/or inner ear. Methods of treating diseases or disorders of the middle ear and/or inner ear, pharmaceutical compositions comprising the conjugates, and methods of inhibiting a Tropomyosin receptor kinase are also provided.
    Type: Application
    Filed: April 12, 2022
    Publication date: August 11, 2022
    Inventors: Charles E. McKenna, Boris A. Kashemirov, Shuting Sun, Kim Nguyen, David Jung, Michael J. McKenna, William Sewell, Judith Kempfle, Woo Seok Kang, Albert Edge
  • Publication number: 20220218638
    Abstract: The present disclosure provides compositions and methods for treating subjects at risk for or with sensorineural hearing loss. Such compositions and methods include modulating the epigenetic status of the cell, or rate of protein degradation, to increase expression and/or levels of Atoh1 protein.
    Type: Application
    Filed: March 30, 2022
    Publication date: July 14, 2022
    Inventors: Albert Edge, Judith Kempfle, Dunia Abdul-Aziz
  • Patent number: 11331391
    Abstract: This invention relates to drug conjugates useful for localized treatment of diseases or disorders of the middle ear and/or inner ear. Methods of treating diseases or disorders of the middle ear and/or inner ear, pharmaceutical compositions comprising the conjugates, and methods of inhibiting a Tropomyosin receptor kinase are also provided.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: May 17, 2022
    Assignees: Massachusetts Eye and Ear Infirmary, University of Southern California
    Inventors: Charles E. McKenna, Boris A. Kashemirov, Shuting Sun, Kim Nguyen, David Jung, Michael J. McKenna, William Sewell, Judith Kempfle, Woo Seok Kang, Albert Edge
  • Patent number: 11298328
    Abstract: The present disclosure provides compositions and methods for treating subjects at risk for or with sensorineural hearing loss. Such compositions and methods include modulating the epigenetic status of the cell, or rate of protein degradation, to increase expression and/or levels of Atoh1 protein.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: April 12, 2022
    Assignee: Massachusetts Eye and Ear Infirmary
    Inventors: Albert Edge, Judith Kempfle, Dunia Abdul-Aziz
  • Patent number: 11286487
    Abstract: The present disclosure provides compositions and methods for treating subjects at risk for or with sensorineural hearing loss by modulating the rate of Atoh1 protein degradation to increase levels of Atoh1 protein.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: March 29, 2022
    Assignee: Massachusetts Eye and Ear Infirmary
    Inventors: Albert Edge, Yen-Fu Cheng, Judith Kempfle, Dunia Abdul-Aziz
  • Publication number: 20200338030
    Abstract: The present disclosure provides compositions and methods for treating subjects at risk for or with sensorineural hearing loss. Such compositions and methods include modulating the epigenetic status of the cell, or rate of protein degradation, to increase expression and/or levels of Atoh1 protein.
    Type: Application
    Filed: March 9, 2020
    Publication date: October 29, 2020
    Inventors: Albert Edge, Judith Kempfle, Dunia Abdul-Aziz
  • Patent number: 10603295
    Abstract: The present disclosure provides compositions and methods for treating subjects at risk for or with sensorineural hearing loss. Such compositions and methods include modulating the epigenetic status of the cell, or rate of protein degradation, to increase expression and/or levels of Atoh1 protein.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: March 31, 2020
    Assignee: Massachusetts Eye and Ear Infirmary
    Inventors: Albert Edge, Judith Kempfle, Dunia Abdul-Aziz
  • Publication number: 20190203210
    Abstract: The present disclosure provides compositions and methods for treating subjects at risk for or with sensorineural hearing loss by modulating the rate of Atoh1 protein degradation to increase levels of Atoh1 protein.
    Type: Application
    Filed: March 19, 2019
    Publication date: July 4, 2019
    Inventors: Albert Edge, Yen-Fu Cheng, Judith Kempfle, Dunia Abdul-Aziz
  • Publication number: 20190030172
    Abstract: This invention relates to drug conjugates useful for localized treatment of diseases or disorders of the middle ear and/or inner ear. Methods of treating diseases or disorders of the middle ear and/or inner ear, pharmaceutical compositions comprising the conjugates, and methods of inhibiting a Tropomyosin receptor kinase are also provided.
    Type: Application
    Filed: January 25, 2017
    Publication date: January 31, 2019
    Inventors: Charles E. McKenna, Boris A. Kashemirov, Shuting Sun, Kim Nguyen, David Jung, Michael J. McKenna, William Sewell, Judith Kempfle, Woo Seok Kang, Albert Edge
  • Publication number: 20170314027
    Abstract: The present disclosure provides compositions and methods for treating subjects at risk for or with sensorineural hearing loss by modulating the rate of Atoh1 protein degradation to increase levels of Atoh1 protein.
    Type: Application
    Filed: August 6, 2015
    Publication date: November 2, 2017
    Inventors: Albert Edge, Yen-Fu Cheng, Judith Kempfle, Dunia Abdul-Aziz
  • Publication number: 20170042842
    Abstract: The present disclosure provides compositions and methods for treating subjects at risk for or with sensorineural hearing loss. Such compositions and methods include modulating the epigenetic status of the cell, or rate of protein degradation, to increase expression and/or levels of Atoh1 protein.
    Type: Application
    Filed: April 28, 2015
    Publication date: February 16, 2017
    Inventors: Albert Edge, Judith Kempfle, Dunia Abdul-Aziz